Fuji Pharmaceutical Industries recorded an securities evaluation loss of \u00a53,519 million in the second quarter of FY2026 September. There has been no change to the consolidated earnings forecast for this term, and the company reported a loss due to the decline in stock valuation of its biosimilar business.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4554","jir_company_name":"Fuji Pharmaceutical Industries Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4554-20260512-02.pdf","jir_short_summary":"Fuji Pharmaceutical Industries recorded an securities evaluation loss of \u00a53,519 million in the second quarter of FY2026 September. There has been no change to the consolidated earnings forecast for this term, and the company reported a loss due to the decline in stock valuation of its biosimilar business.","jir_summary":"### Overview of Business Performance\nIn the second quarter of FY2026 September, Fuji Pharmaceutical Industries recorded a securities evaluation loss of \u00a53,519 million due to a decline in the market value of investment securities. This was caused by a decrease in stock valuation of the company's global licenser Alvotech Holding S.A. for its biosimilar business. The company adopts the declining balance method for quarterly valuation. There has been no change to the consolidated earnings forecast for this term, and the company continues to aim for steady business operations.\n\n### Future Outlook and Impact on Shareholders\nThe company states that there are no changes to the FY2026 September consolidated earnings forecast and emphasizes that the securities evaluation loss is a temporary occurrence. While valuation losses may fluctuate with stock price movements, the company plans to continue its growth strategy and expand its biosimilar business. For investors, although there are short-term valuation losses, the focus remains on the robustness of the long-term business strategy.","jir_financial_highlights":"Securities evaluation loss: \u00a53,519 million (Prior to this, \u00a52,457 million was recognized in the first quarter of FY2026 September)","jir_category":"","jir_hashtags":"#FujiPharmaceuticalIndustries, #FinancialResults, #JapanStocks","jir_key_figures":"Securities evaluation loss: \u00a53,519 million\nAssessment loss in the first quarter: \u00a52,457 million\nNo change to this term's earnings forecast","jir_meta_title":"\u3010Fuji Pharmaceutical Industries\u3011Recognition of Securities Evaluation Loss and Future Outlook | May 2026","jir_meta_description":"Fuji Pharmaceutical Industries recorded an securities evaluation loss of \u00a53,519 million in the second quarter of FY2026 September. There are no changes to this term's earnings forecast, and the company continues its long-term strategy.","jir_og_title":"\u3010Fuji Pharmaceutical Industries\u3011Securities Loss and Future Outlook | May 2026","jir_og_description":"Fuji Pharmaceutical Industries recorded securities evaluation loss in FY2026 September second quarter. The company will continue to maintain steady business operations.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17504,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48419","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n